Choose AliveCor for your clinical trials.
Connect for a custom integration strategy that sets your research apart.
Our Technology
Our Solutions
(855) 338-8800
Partnership delivers a participant-centric cardiac monitoring solution that captures ECG data onsite or remotely, while reducing costs and burden for trial sites and patients.
Mountain View, CA, February 20, 2026 - Ametris, a global digital health solutions provider, transforming real-world patient data into validated clinical evidence, today announced a partnership with AliveCor, a global leader in providing electrocardiogram (ECG) solutions for clinical research. This collaboration integrates AliveCor’s medical-grade cardiac monitoring solution, including the world’s first FDA-cleared 6-lead ECG device, into the Ametris Digital Health Technology (DHT) platform. The integration expands Ametris’ connected device ecosystem and strengthens digital cardiac endpoint capabilities for clinical trials.
Biopharma sponsors can now incorporate medical-grade, remote cardiac assessments into trial designs, improving patient accessibility while maintaining rigorous oversight. By embedding AliveCor’s validated ECG data directly into the Ametris platform, sponsors can collect high-quality cardiac data in real-world settings, reducing site burden and patient travel while supporting more scalable trial execution.
Cardiac safety assessments are a routine component of many clinical development programs, not only in cardiology trials, but also in therapeutic areas such as oncology and neurology where investigational therapies may influence cardiac repolarization. The traditional 12-lead ECG, while well established, typically requires in-clinic visits and specialized infrastructure, which can limit flexibility in modern hybrid and decentralized trial designs.
The Ametris–AliveCor collaboration introduces a scalable, patient-friendly alternative that enables remote detection of seven of the most common heart rhythms and InstantQT™, which displays QT and QTc interval measurements in seconds.* When paired with clinician overreads, the solution allows for visualization of over 20 additional heart rhythms, which expands detection capabilities to identify a broader range of clinical conditions. By extending cardiac data collection into the home environment, biopharma sponsors can support more consistent, flexible monitoring while reducing the costs and operational demands associated with frequent site visits.
“By integrating our ECG technology with the Ametris platform, we are removing the traditional barriers to remote monitoring. Through AI-driven, self-administered data capture, critical heart rhythm and QT analysis is delivered in seconds, ensuring data integrity while significantly reducing participant and site burden,” said Frank Padron, Vice President & General Manager, BioPharma at AliveCor. “This helps companies develop life-saving therapies while boosting participant diversity and retention by reaching populations in the environments where they actually live.”
As part of the agreement, AliveCor joins the Ametris Accelerant™ Partnership Program, ensuring validated interoperability, streamlined deployment, and coordinated support for sponsors. The collaboration also establishes a foundation for joint thought leadership focused on advancing best practices for remote cardiac assessment across therapeutic areas.
“The future of clinical research depends on delivering high-quality, site-grade data in ways that align with how patients live and how modern studies are designed,” said Mandana Varahrami, Chief Product Officer at Ametris. “Integrating AliveCor’s medical-grade ECG technology expands the depth and accessibility of cardiac data for sponsors and reinforces our commitment to combining objective digital clinical measures within a connected ecosystem to accelerate evidence generation and advance the development of new therapies.”
AliveCor will join Ametris as a Gold Sponsor at the upcoming ADDS 2026 annual scientific meeting, Feb 23-25 in Atlanta. The Ametris Digital Data Summit (ADDS) serves as a premier collaborative forum for biopharma leaders, regulators, scientists, and digital health innovators. The three-day program includes scientific presentations, real-world case studies, expert panel discussions, and a dedicated scientific poster session featuring clinical research involving the use of DHTs. The event also provides meaningful networking opportunities designed to foster collaboration and advance the adoption of digital measurement solutions across therapeutic areas. Learn more at: https://adds.ametris.com/2026/atlanta/home
About Ametris
Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support to simplify every phase of a clinical trial—from study design to submission. Backed by two decades of experience and a collaborative approach, Ametris empowers research teams to run smarter trials, reduce patient burden, and accelerate therapeutic innovation.
About AliveCor
AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the inaugural TIME World's Top Health Tech Companies 2025 list—recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 350 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L to detect 39 cardiac conditions (16 arrhythmias and 23 morphologies), was designed exclusively for use by healthcare providers. AliveCor's enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook.
*QT measurements made using the EK12 ECG algorithm.
Choose AliveCor for your clinical trials.
Connect for a custom integration strategy that sets your research apart.